Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Power3 Medical Able to Offer Blood-Based Tests for Detection of Breast Cancer and Neurodegenerative Diseases after Receiving CLIA High-Complexity Certification
May 1st, 2007
Power3 Medical Products, Inc. (OTC: PWRM, www.Power3Medical.com), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for neurodegenerative disease and breast cancer, announced that it has received a certification to begin offering CLIA-compliant high complexity medical testing services. Concurrently, Power3 announced that Dr. Essam Sheta, its director of Biochemistry, will serve as laboratory director for CLIA-compliant testing. The CLIA (Clinical Laboratory Improvement Amendments) was passed by the U.S. Congress in 1988 to establish quality standards for all laboratory testing, and...
Source: Cancer Weekly (2007-05-01)
|
